BC
SGMO

Burleson & Co’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Burleson & Co’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$2.45K Hold
780
– – ﹤0.01% 329
2022
Q3 		$4K Hold
780
– – ﹤0.01% 319
2022
Q2 		$3K Hold
780
– – ﹤0.01% 323
2022
Q1 		$5K Hold
780
– – ﹤0.01% 305
2021
Q4 		$6K Hold
780
– – ﹤0.01% 281
2021
Q3 		$7K Hold
780
– – ﹤0.01% 275
2021
Q2 		$9K Hold
780
– – ﹤0.01% 269
2021
Q1 		$10K Buy
+780
New +$10.5K ﹤0.01% 254

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Burleson & Co's SGMO Position: Q4 2022 in Review

Burleson & Co held its SANGAMO THERAPEUTICS INC (SGMO) position steady in Q4 2022 at 780 shares worth $2.45K. The position accounts for ﹤0.01% of the portfolio, ranked #329.

Burleson & Co first reported a position in SGMO in Q1 2021 and has held it in 8 quarters since. The position peaked at $10K in Q1 2021. 182 funds tracked by Wall St. Rank hold SGMO as of Q4 2022.

  • Burleson & Co held 780 shares of SANGAMO THERAPEUTICS INC worth $2.45K as of Q4 2022.
  • Burleson & Co left its SANGAMO THERAPEUTICS INC share count unchanged in Q4 2022.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Burleson & Co's portfolio in Q4 2022, its #329 holding.
  • Burleson & Co first reported a position in SANGAMO THERAPEUTICS INC in Q1 2021 and has held it in 8 quarters since.
  • Burleson & Co's SANGAMO THERAPEUTICS INC position peaked at $10K in Q1 2021.
  • 182 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2022.

Based on Burleson & Co's 13F filing for Q4 2022, filed 31 Jan 2023.